A randomized, placebo-controlled crossover trial (PolyPAUSE, n=90 mildly hypercholesterolemic postmenopausal women) tested an 8-week daily polyphenol cocktail delivering ellagitannins/ellagic acid (312 mg), resveratrol (133 mg), and isoflavones (166 mg). Paradoxically, total cholesterol rose 7%, LDL-cholesterol 9.5%, and triglycerides 16% — yet oxidized LDL fell significantly (p<0.001), ApoB trended downward, and three LDL-quality ratios (LDLc/ApoB, oxLDL/LDLc, oxLDL/ApoB) all improved. Equol producers — women whose gut microbiota convert daidzein to equol — showed a striking 65% oxLDL reduction, and the combined UMA+equol producer+lunularin non-producer cluster achieved 60%.
This finding reframes a genuinely uncomfortable question: does a rising LDL number matter less if the particles are larger, fewer, and far less oxidized? Oxidized LDL is increasingly recognized as the atherogenically active fraction — standard LDL-cholesterol is an imperfect proxy. The polyphenol-induced lipid increase likely reflects mobilization or altered hepatic processing rather than increased cardiovascular hazard, though causal mechanism remains unresolved. The metabotype stratification is the study's most consequential contribution: gut microbial capacity to metabolize polyphenols — not supplementation dose — appears to dictate cardiometabolic outcome. This aligns with emerging microbiome-cardiovascular crosstalk research. Limitations include the relatively short 8-week intervention, absence of hard cardiovascular endpoints, and self-selected crossover design. Still, this is a genuinely paradigm-nudging result — it argues that population-level polyphenol guidelines without microbiome phenotyping may obscure significant individual variation in therapeutic benefit.
